Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KDNYNYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKDNYChinook Therapeutics$40.39$39.86$18.34▼$40.51$2.90B0.341.19 million shsN/ANVSNovartis$121.90-1.5%$115.08$96.06▼$124.45$257.50B0.591.59 million shs955,240 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKDNYChinook Therapeutics0.00%0.00%0.00%0.00%0.00%NVSNovartis0.00%+1.33%+3.59%+15.23%+14.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKDNYChinook TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVSNovartis1.6585 of 5 stars1.03.02.50.02.70.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKDNYChinook Therapeutics 0.00N/AN/AN/ANVSNovartis 2.00Hold$123.671.45% UpsideCurrent Analyst Ratings BreakdownLatest NVS and KDNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025NVSNovartisBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKDNYChinook Therapeutics$6.13M473.15N/AN/A$6.91 per share5.85NVSNovartis$53.22B4.84$10.70 per share11.39$21.59 per share5.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKDNYChinook Therapeutics-$187.87M-$3.52N/AN/AN/A-4,199.93%-58.28%-44.72%N/ANVSNovartis$11.94B$6.4019.0513.841.6824.70%39.44%16.43%7/17/2025 (Estimated)Latest NVS and KDNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/17/2025Q2 2025NVSNovartis$2.37N/AN/AN/A$13.94 billionN/A4/29/2025Q1 2025NVSNovartis$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKDNYChinook TherapeuticsN/AN/AN/AN/AN/ANVSNovartis$2.592.12%N/A40.47%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKDNYChinook TherapeuticsN/A5.825.82NVSNovartis0.560.790.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKDNYChinook Therapeutics95.15%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipKDNYChinook Therapeutics16.79%NVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKDNYChinook Therapeutics21471.81 million59.75 millionOptionableNVSNovartis75,8832.11 billion2.11 billionOptionableNVS and KDNY HeadlinesRecent News About These CompaniesWorld Investment Advisors Raises Holdings in Novartis AG (NYSE:NVS)5 hours ago | marketbeat.comNovartis AG (NYSE:NVS) Given Consensus Recommendation of "Hold" by BrokeragesJuly 6 at 2:16 AM | marketbeat.comCatalyst Capital Advisors LLC Increases Holdings in Novartis AG (NYSE:NVS)July 4 at 8:38 AM | marketbeat.comTimber Creek Capital Management LLC Sells 5,799 Shares of Novartis AG (NYSE:NVS)July 4 at 8:15 AM | marketbeat.comDavidson Trust Co. Sells 5,771 Shares of Novartis AG (NYSE:NVS)July 4 at 6:25 AM | marketbeat.comNovartis AG (NYSE:NVS) Shares Sold by Principal Financial Group Inc.July 4 at 5:56 AM | marketbeat.comAllspring Global Investments Holdings LLC Purchases 14,057 Shares of Novartis AG (NYSE:NVS)July 4 at 4:05 AM | marketbeat.comNovartis announces top-line results from phase III GCAptAIN study of Cosentyx in giant cell arteritisJuly 3 at 12:33 AM | pharmabiz.comPNovartis’ hopes dashed for GCA indication for blockbusterJuly 3 at 7:32 PM | thepharmaletter.comTLate-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune ConditionJuly 3 at 7:32 PM | biospace.comBNovartis drug flunks phase 3 test in giant cell arteritisJuly 3 at 7:32 PM | pharmaphorum.comPNovartis fails in late-stage trial for Cosentyx in giant cell arteritisJuly 3 at 7:32 PM | msn.comNovartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns BullishJuly 3 at 7:32 PM | msn.comNovartis' Cosentyx Misses Primary Goal in Arteritis Phase III StudyJuly 3 at 11:35 AM | zacks.comD.A. Davidson & CO. Sells 65,251 Shares of Novartis AG (NYSE:NVS)July 3 at 8:46 AM | marketbeat.comRossby Financial LCC Makes New $288,000 Investment in Novartis AG (NYSE:NVS)July 3 at 5:18 AM | marketbeat.comNovartis drug Cosentyx fails late-stage trial for artery diseaseJuly 3 at 2:42 AM | reuters.comNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)July 3 at 2:25 AM | prnewswire.comNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)July 3 at 2:15 AM | globenewswire.comUBS Sticks to Its Hold Rating for Novartis AG (NOVN)July 2, 2025 | theglobeandmail.comBuy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July StartJuly 2, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVS and KDNY Company DescriptionsChinook Therapeutics NASDAQ:KDNYChinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Novartis NYSE:NVS$121.90 -1.91 (-1.54%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$123.50 +1.60 (+1.32%) As of 07/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
